Literature DB >> 25822883

The role of statins in inflammatory vasculitides.

Adriana H Tremoulet1.   

Abstract

While the statins are best known for their cholesterol lowering capabilities, they also appear to have anti-inflammatory, anti-oxidant and endothelial-repairing properties that have raised the question as to whether this class of drugs can be of benefit in non-atherosclerotic, acute and chronic vasculitides. These effects, independent of the lipid-lowering effects, make the statins a class of drugs that are primed for repurposing and being used in disease states where innate and adaptive immunity and endothelial damage play a key role. Thus far, statins have been used in Behcet's, rheumatoid arthritis and Kawasaki disease with some promising results. Further study is needed to better understand the innate and adaptive immunological response to statins in cardiovascular diseases as well as the full potential of statins in acute and chronic inflammatory vasculitides.

Entities:  

Keywords:  Atorvastatin; Behcet’s; Kawasaki disease; repurposing; rheumatoid arthritis

Mesh:

Substances:

Year:  2015        PMID: 25822883     DOI: 10.3109/08916934.2015.1027818

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  8 in total

Review 1.  2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease.

Authors:  Frank Zhu; Jocelyn Y Ang
Journal:  Curr Infect Dis Rep       Date:  2021-02-06       Impact factor: 3.725

2.  Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

Authors:  Adriana H Tremoulet; Sonia Jain; Pei-Ni Jone; Brookie M Best; Elizabeth H Duxbury; Alessandra Franco; Beth Printz; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glodé; Feng He; Robert L Padilla; Chisato Shimizu; Emelia Bainto; Joan Pancheri; Harvey J Cohen; John C Whitin; Jane C Burns
Journal:  J Pediatr       Date:  2019-09-24       Impact factor: 4.406

Review 3.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

4.  Atorvastatin prevents glomerular extracellular matrix formation by interfering with the PKC signaling pathway.

Authors:  Yan-Hua Xiao; Xiao-Yun He; Qing Han; Fan Yang; Su-Xian Zhou
Journal:  Mol Med Rep       Date:  2018-03-09       Impact factor: 2.952

Review 5.  Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks.

Authors:  Alessandra Marchesi; Isabella Tarissi de Jacobis; Donato Rigante; Alessandro Rimini; Walter Malorni; Giovanni Corsello; Grazia Bossi; Sabrina Buonuomo; Fabio Cardinale; Elisabetta Cortis; Fabrizio De Benedetti; Andrea De Zorzi; Marzia Duse; Domenico Del Principe; Rosa Maria Dellepiane; Livio D'Isanto; Maya El Hachem; Susanna Esposito; Fernanda Falcini; Ugo Giordano; Maria Cristina Maggio; Savina Mannarino; Gianluigi Marseglia; Silvana Martino; Giulia Marucci; Rossella Massaro; Christian Pescosolido; Donatella Pietraforte; Maria Cristina Pietrogrande; Patrizia Salice; Aurelio Secinaro; Elisabetta Straface; Alberto Villani
Journal:  Ital J Pediatr       Date:  2018-08-30       Impact factor: 2.638

6.  Sphingosine Kinase 1 Plays an Important Role in Atorvastatin-Mediated Anti-Inflammatory Effect against Acute Lung Injury.

Authors:  Lan Wu; Yan Cheng; Shunxiang Peng; Wensheng Zhang; Chaoxiong Zhang
Journal:  Mediators Inflamm       Date:  2021-12-21       Impact factor: 4.711

Review 7.  2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease.

Authors:  Frank Zhu; Jocelyn Y Ang
Journal:  Curr Infect Dis Rep       Date:  2021-02-06       Impact factor: 3.725

Review 8.  The Clinical Diagnosis and Management of Kawasaki Disease: a Review and Update.

Authors:  Frank H Zhu; Jocelyn Y Ang
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.